How I Treat Highly Aggressive Lymphomas: Burkitt, Double-Hit, B-Cell, and Unclassifiable with Features Intermediate between DLBCL and Burkitt Lymphoma
Upon viewing this session, you will be able to apply the new WHO classification 2016 update to the diagnosis of high grade lymphomas, and differentiate various subentities, select optimal therapeutic approaches using currently available evidence for the treatment of double hit lymphoma and Burkitt lymphoma, and define an optimal diagnostic approach for newly diagnosed aggressive lymphomas to enable treatment selection.
Jonathan Friedberg, MD, University of Rochester
Active, International, Emeritus, and Honorary Members
Associate, International Associate, Student, and Resident Members